@article{discovery10051921,
          number = {11},
            year = {2018},
           month = {November},
         journal = {Alzheimer's \& Dementia},
            note = {Copyright {\copyright} 2018 The Authors. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).},
           pages = {1470--1481},
           title = {CSF biomarkers of Alzheimer's disease concord with amyloid-{\ensuremath{\beta}} PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts},
          volume = {14},
        keywords = {Amyloid PET concordance, Amyloid-{\ensuremath{\beta}} (1-42), Biomarker validation, CSF biomarkers, Clinical progression, Cutoffs, Phosphorylated tau (pTau), Total tau (tTau)},
        abstract = {INTRODUCTION: We studied whether fully automated Elecsys cerebrospinal fluid (CSF) immunoassay results were concordant with positron emission tomography (PET) and predicted clinical progression, even with cutoffs established in an independent cohort. METHODS: Cutoffs for Elecsys amyloid-{\ensuremath{\beta}}1-42 (A{\ensuremath{\beta}}), total tau/A{\ensuremath{\beta}}(1-42), and phosphorylated tau/A{\ensuremath{\beta}}(1-42) were defined against [18F]flutemetamol PET in Swedish BioFINDER (n�=�277) and validated against [18F]florbetapir PET in Alzheimer's Disease Neuroimaging Initiative (n�=�646). Clinical progression in patients with mild cognitive impairment (n�=�619) was studied. RESULTS: CSF total tau/A{\ensuremath{\beta}}(1-42) and phosphorylated tau/A{\ensuremath{\beta}}(1-42) ratios were highly concordant with PET classification in BioFINDER (overall percent agreement: 90\%; area under the curve: 94\%). The CSF biomarker statuses established by predefined cutoffs were highly concordant with PET classification in Alzheimer's Disease Neuroimaging Initiative (overall percent agreement: 89\%-90\%; area under the curves: 96\%) and predicted greater 2-year clinical decline in patients with mild cognitive impairment. Strikingly, tau/A{\ensuremath{\beta}} ratios were as accurate as semiquantitative PET image assessment in predicting visual read-based outcomes. DISCUSSION: Elecsys CSF biomarker assays may provide reliable alternatives to PET in Alzheimer's disease diagnosis.},
            issn = {1552-5279},
             url = {https://doi.org/10.1016/j.jalz.2018.01.010},
          author = {Hansson, O and Seibyl, J and Stomrud, E and Zetterberg, H and Trojanowski, JQ and Bittner, T and Lifke, V and Corradini, V and Eichenlaub, U and Batrla, R and Buck, K and Zink, K and Rabe, C and Blennow, K and Shaw, LM and Swedish BioFINDER study group, . and Alzheimer's Disease Neuroimaging Initiative, .}
}